TUSTIN, Calif., March 2, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. PPHM PPHMP, a biopharmaceutical company focused on advancing bavituximab, a novel immuno-oncology antibody targeting the highly immunosuppressive phosphatidylserine (PS) signaling pathway, towards commercialization and providing integrated cGMP clinical and commercial bio-manufacturing services, announced that Steven W. King, president and chief executive officer, will present a company update at the 27th Annual ROTH Conference on Monday, March 9th, 2015 at 10:00 AM Pacific Time (1:00 PM Eastern Time) at The Ritz-Carlton Laguna Niguel in Dana Point, California.
Peregrine's presentation at the ROTH conference will be webcast live and available for replay for 30 days at: http://ir.peregrineinc.com/events.cfm
About Peregrine Pharmaceuticals, Inc.
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a pipeline of novel drug candidates in clinical trials for the treatment and diagnosis of cancer. The company's lead immuno-oncology candidate, bavituximab, is in Phase III development for the treatment of second-line non-small lung cancer (the "SUNRISE trial") along with several investigator-sponsored trials evaluating other treatment combinations and additional oncology indications. The company is also advancing a molecular imaging agent, 124I-PGN650, in an exploratory clinical trial for the imaging of multiple solid tumor types. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and third-party customers. Additional information about Peregrine can be found at www.peregrineinc.com.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.